Do analysts rate BVXP or PRTC?

PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 335.68%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings & valuation, BVXP or PRTC?

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventix £12.54M 6.25 £8.12M £140.52 10.67 PureTech Health £4.66M 60.92 -£91.86M -£46.00 N/A

Which has higher earnings and valuation, ARIX or BVXP?

Arix Bioscience has higher revenue and earnings than Bioventix. Arix Bioscience is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A Bioventix £12.54M 6.25 £8.12M £140.52 10.67

Do analysts prefer BVXP or BTG?

BTG has a consensus price target of GBX 160, suggesting a potential upside of 50.94%. Given BTG's stronger consensus rating and higher probable upside, analysts plainly believe BTG is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BTG 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation & earnings, BVXP or BTG?

Bioventix has higher earnings, but lower revenue than BTG. Bioventix is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventix £12.54M 6.25 £8.12M £140.52 10.67 BTG £168.50M 1.01 N/A £5.10 20.78

Is BVXP or BTG more profitable?

Bioventix has a net margin of 59.30% compared to BTG's net margin of 0.00%. Bioventix's return on equity of 65.83% beat BTG's return on equity. Company Net Margins Return on Equity Return on Assets Bioventix 59.30% 65.83% 54.07% BTG N/A N/A N/A

Bioventix (BVXP) Competitors

GBX 1,500 0.00 (0.00%)

As of 12:03 PM Eastern

Compare

BVXP vs. HZD, PRTC, VRP, ARIX, and BTG

Should you buy Bioventix stock or one of its competitors? MarketBeat compares Bioventix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventix include Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), and BTG (BTG).

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Bioventix (LON:BVXP) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Bioventix has higher earnings, but lower revenue than Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.25	£8.12M	£140.52	10.67
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

20.6% of Bioventix shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
Bioventix	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Bioventix has a net margin of 59.30% compared to Horizon Discovery Group plc (HZD.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Summary

Bioventix beats Horizon Discovery Group plc (HZD.L) on 7 of the 8 factors compared between the two stocks.

How does Bioventix compare to PureTech Health?

Bioventix (LON:BVXP) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.25	£8.12M	£140.52	10.67
PureTech Health	£4.66M	60.92	-£91.86M	-£46.00	N/A

In the previous week, PureTech Health had 11 more articles in the media than Bioventix. MarketBeat recorded 11 mentions for PureTech Health and 0 mentions for Bioventix. PureTech Health's average media sentiment score of 1.35 beat Bioventix's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Bioventix	Neutral
PureTech Health	Positive

Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, indicating that its stock price is 23% less volatile than the broader market.

Bioventix has a net margin of 59.30% compared to PureTech Health's net margin of -2,355.32%. Bioventix's return on equity of 65.83% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
PureTech Health	-2,355.32%	-31.98%	-13.39%

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 33.5% of PureTech Health shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 13.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 335.68%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

PureTech Health beats Bioventix on 9 of the 16 factors compared between the two stocks.

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Bioventix (LON:BVXP) and Verona Pharma plc (VRP.L) (LON:VRP) are related small-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

20.6% of Bioventix shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bioventix has higher revenue and earnings than Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.25	£8.12M	£140.52	10.67
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Bioventix has a net margin of 59.30% compared to Verona Pharma plc (VRP.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.

Company	Overall Sentiment
Bioventix	Neutral
Verona Pharma plc (VRP.L)	Neutral

Summary

Bioventix beats Verona Pharma plc (VRP.L) on 8 of the 8 factors compared between the two stocks.

How does Bioventix compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Arix Bioscience has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, meaning that its share price is 45% less volatile than the broader market.

Arix Bioscience has a net margin of 105.64% compared to Bioventix's net margin of 59.30%. Bioventix's return on equity of 65.83% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Bioventix	59.30%	65.83%	54.07%

Arix Bioscience has higher revenue and earnings than Bioventix. Arix Bioscience is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Bioventix	£12.54M	6.25	£8.12M	£140.52	10.67

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 20.6% of Bioventix shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by company insiders. Comparatively, 6.2% of Bioventix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Arix Bioscience's average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
Arix Bioscience	Neutral
Bioventix	Neutral

Summary

Arix Bioscience beats Bioventix on 7 of the 10 factors compared between the two stocks.

How does Bioventix compare to BTG?

Bioventix (LON:BVXP) and BTG (LON:BTG) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Bioventix has a net margin of 59.30% compared to BTG's net margin of 0.00%. Bioventix's return on equity of 65.83% beat BTG's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
BTG	N/A	N/A	N/A

Bioventix has higher earnings, but lower revenue than BTG. Bioventix is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.25	£8.12M	£140.52	10.67
BTG	£168.50M	1.01	N/A	£5.10	20.78

BTG has a consensus price target of GBX 160, suggesting a potential upside of 50.94%. Given BTG's stronger consensus rating and higher probable upside, analysts plainly believe BTG is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

20.6% of Bioventix shares are held by institutional investors. Comparatively, 20.3% of BTG shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 19.7% of BTG shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 10.0%. BTG pays an annual dividend of GBX 4.40 per share and has a dividend yield of 4.2%. Bioventix pays out 106.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BTG pays out 86.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, BTG had 3 more articles in the media than Bioventix. MarketBeat recorded 3 mentions for BTG and 0 mentions for Bioventix. BTG's average media sentiment score of 0.17 beat Bioventix's score of 0.00 indicating that BTG is being referred to more favorably in the news media.

Company	Overall Sentiment
Bioventix	Neutral
BTG	Neutral

Summary

BTG beats Bioventix on 9 of the 16 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVXP vs. The Competition

Export

Metric	Bioventix	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£78.38M	£11.79B	£6.93B	£2.87B
Dividend Yield	9.93%	2.73%	2.60%	6.13%
P/E Ratio	10.67	794.00	281.16	369.49
Price / Sales	6.25	745.84	575.77	83,955.53
Price / Cash	30.89	72.42	71.79	27.89
Price / Book	6.52	10.72	12.86	7.07
Net Income	£8.12M	£2.82B	£3.49B	£5.89B
7 Day Performance	-0.66%	2.82%	2.63%	1.18%
1 Month Performance	-5.66%	-1.32%	-2.64%	0.90%
1 Year Performance	-41.12%	195.95%	76.00%	75.31%

Bioventix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVXP Bioventix	N/A	GBX 1,500 flat	N/A	-38.8%	£78.38M	£12.54M	10.67	12
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.4968 of 5 stars	GBX 123 -0.3%	GBX 508 +313.0%	-14.1%	£299.40M	£4.66M	N/A	300	Gap Down
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BVXP) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventix (BVXP) Competitors

BVXP vs. HZD, PRTC, VRP, ARIX, and BTG

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Bioventix compare to PureTech Health?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Summary

How does Bioventix compare to Arix Bioscience?

Summary

How does Bioventix compare to BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventix (BVXP) Competitors

BVXP vs. HZD, PRTC, VRP, ARIX, and BTG

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Which has stronger earnings & valuation, BVXP or HZD?

Do insiders and institutionals hold more shares of BVXP or HZD?

Does the media refer more to BVXP or HZD?

Is BVXP or HZD more profitable?

Summary

How does Bioventix compare to PureTech Health?

Which has higher earnings & valuation, BVXP or PRTC?

Does the media refer more to BVXP or PRTC?

Which has more volatility & risk, BVXP or PRTC?

Is BVXP or PRTC more profitable?

Do insiders and institutionals have more ownership in BVXP or PRTC?

Do analysts rate BVXP or PRTC?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Do institutionals and insiders have more ownership in BVXP or VRP?

Which has stronger valuation and earnings, BVXP or VRP?

Is BVXP or VRP more profitable?

Does the media refer more to BVXP or VRP?

Summary

How does Bioventix compare to Arix Bioscience?

Which has more risk and volatility, ARIX or BVXP?

Is ARIX or BVXP more profitable?

Which has higher earnings and valuation, ARIX or BVXP?

Do insiders & institutionals have more ownership in ARIX or BVXP?

Does the media favor ARIX or BVXP?

Summary

How does Bioventix compare to BTG?

Is BVXP or BTG more profitable?

Which has stronger valuation & earnings, BVXP or BTG?

Do analysts prefer BVXP or BTG?

Do insiders & institutionals believe in BVXP or BTG?

Is BVXP or BTG a better dividend stock?

Does the media favor BVXP or BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools